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The possible role of iron in the degeneration of nervous cells in Parkinson’s disease (PD) was studied with the use of Mo¨ssbauer
spectroscopy (MS) and enzyme-linked immunoabsorbent assay (ELISA). Mo¨ssbauer data were obtained at 90 and 4.1 K from 21 samples of
control and 9 samples of parkinsonian substantia nigra (SN). Mo¨ssbauer spectra were very similar to those observed in ferritin. Small
differences were detected between the spectra obtained from PD and from control SN, and could be due to a slight difference in the
composition of the ferritin-like iron cores or due to the presence of about 8% of non-ferritin-like iron in parkinsonian SN. ELISA studies from
11 controls and 6 parkinsonian SN showed a decrease in the concentration of L-chains in wet tissues of PD-SN compared to control SN. The
decrease in the amount of L subunits may correspond to a decreased ability of this ferritin to keep iron in a safe form. Iron released from
ferritin or neuromelanin (NM) may be the source of such iron, which may cause the difference in the Mo¨ssbauer spectra and may trigger
oxidative stress leading to cell death.
D 2003 Elsevier B.V. All rights reserved.Keywords: Parkinson’s disease; Nigral iron; Mo¨ssbauer spectroscopy; ELISA; Ferritin; Oxidative stress1. Introduction
Parkinson’s disease (PD) is a progressive degeneration of
nervous cells in substantia nigra (SN), a small iron-rich
structure [1] of about 500 mg, located symmetrically in the
mesencephalon. Oxidative stress, which causes an overpro-
duction of free radicals, is believed to be one of the possible
mechanisms responsible for the death of nigral cells in PD.
Oxidative stress may be triggered by the Fenton reaction, in
which iron plays a crucial role [2]. The Fenton reaction may
be initiated by a small amount of loosely bound iron, which
may cause damage to the tissues. The present studies were an
attempt to detect whether such iron is present in SN of PD
patients and what the possible origin of such iron could be.
Iron may be stored within tissues in a non-toxic form.
The main iron storage protein in all living species (plants,
bacteria, and mammals) is ferritin, which protects tissues
from the toxic influence of iron. Ferritin is also the main0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: erika@vms.huji.ac.il (E.R. Bauminger).iron-binding compound in the brain [3]. Ferritins are com-
posed of a protein shell with an outer diameter of about 12
nm and an inner diameter of about 8 nm. The protein is
composed of 24 subunits. Mammalian ferritins are com-
posed of two types of subunits, L (light) and H (heavy)
chains, which have different functions. In iron storage
organs like the liver, L chains are dominant (L-rich ferritin),
whereas H chains are the dominant subunits in the heart and
in the brain (H-rich ferritin) [4]. H chains contain ferrox-
idase centers and convert rapidly divalent to trivalent iron,
which is then stored within the ferritin molecule. H-ferritin
is dominant in organs, which require little iron storage. L-
chains lack the ferroxidase center and are slow in seques-
tering iron, yet promote the building of the iron core for
long-term storage [5].
Iron concentrations in SN of normal subjects (control)
were found by neutron activation analysis to be stable above
the age of 16 [6]. H- and L-ferritins were found to increase
substantially with age in control SN, yet not in parkinsonian
SN [7]. Iron can be stored within the protein shell forming a
hydrous iron (III)-oxide-mineral core similar to ferrihydrite.
It can contain between 0 and 4800 iron atoms. The mineral
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The cores differ somewhat in different species and organs,
and vary in composition, crystallinity and size [5]. Ferrihy-
drite itself is a poorly ordered hydrous iron oxide with the
approximate formula (5Fe2O39H2O) [8].
Iron in SN may also be stored in neuromelanin (NM) [6],
a black pigment present in neurons of SN. According to X-
ray diffraction studies, NM has a multi-layer, graphite-like,
three-dimensional structure [9]. It is highly capable to attract
iron and other metals and may therefore protect tissues from
damage caused by free iron. As ferritin was not detected in
human SN neurons [10], it has been suggested that NM is
the major iron storage compound in SN neurons in healthy
individuals [6]. It was recently reported, however, that
melanized nervous cells of human SN contain H-rich ferritin
[11]. Mo¨ssbauer effect measurements showed that most of
the iron in NM isolated from SN is ferritin-like iron,
arranged as polynuclear hydrous iron oxide aggregates
(Ref. [12] and our own unpublished data). EPR measure-
ments showed that besides such aggregates, also isolated
Fe(III) ions are present in purified NM of SN [13]. Accord-
ing to Zecca et al. [6], iron bound to NM may constitute
10–20% of the total iron in SN of healthy elderly subjects,
the rest being stored mainly in ferritin of glial cells, outside
neurons.
For the assessment of possible differences in iron binding
between parkinsonian and control SN, we used Mo¨ssbauer
spectroscopy (MS) [14,15]. Mo¨ssbauer spectra and their
temperature dependence obtained from different iron com-
pounds differ mostly from each other and the technique can
therefore often be used as a fingerprint technique to identify
iron compounds and the ion configuration around iron.
Mo¨ssbauer spectra of ferritin show, due to the small size
of the iron cores in these proteins, the phenomenon of
superparamagnetism, exhibiting two lines (a doublet) above
the blocking temperature and six lines (a sextet) below the
blocking temperature [16]. The spectra display a doublet at
90 K and a sextet at 4.1 K [17]. Due to the non-homoge-
neous structure of ferrihydrite and the ferritin iron core,
computer fits to 90 K spectra with one symmetrical doublet
are of a relatively poor quality and a small asymmetry of the
doublets can be detected in most spectra [18,19]. This
asymmetry was never quantified. Mo¨ssbauer spectra of
SN showed spectra, both in PD and control, similar to those
of ferritin [14]. Iron cores were observed by electron
microscopy (EM) in ferritin in whole tissues of SN and in
ferritin isolated from human control SN. Our preliminary
study on the quantification of this asymmetry indicated a
small difference between the asymmetry obtained in spectra
from PD and control SN [15].
Mo¨ssbauer spectra obtained from NM isolated from SN
also show ferritin-like spectra, exhibiting the phenomenon of
superparamagnetism. However, the blocking temperature is
above 77 K for NM, while it is below 40 K for ferritin [17].
It is not well established whether there is any difference
between the ferritin levels in parkinsonian and control SNs.While Dexter et al. [20] found lower ferritin concentrations
in parkinsonian SN, Riederer et al. [21] found higher
concentrations and Mann et al. [22] found the same levels
of ferritin in parkinsonian and control SN. Connor et al. [7]
found a small decrease in H ferritin levels in parkinsonian
SN as compared to control, but a much larger decrease in
the amount of L-ferritin in diseased SN. One goal of the
present study was to assess again the amount of H and L
chains of ferritin in SN from PD and control brains. To
accomplish this, the enzyme-linked immunoabsorbent assay
(ELISA) method was applied.2. Materials and methods
2.1. MS
Mo¨ssbauer spectra were obtained from 21 samples of
control SN and 9 samples of parkinsonian SN. The age at
death in both groups did not differ significantly, being
64F 6 years for controls and 70F 4 years for PD. The
duration of the disease ranged between 4 and 7 years, and all
PD patients died in advanced stages of the disease (4 and 5
according to Hoehn and Yahr scale [23]). The diagnosis of
idiopathic PD was made on both clinical and immunohis-
tochemical grounds, as described previously [14]. The
control samples were taken from patients who died of
non-neurological diseases. The autopsy was performed
within 48 h after death. The samples used for Mo¨ssbauer
studies were separated from the brain at autopsy using
plastic blades.
For MS, samples of SN tissues weighing between 200
and 500 mg were placed in lucite sample holders, frozen
immediately and kept in liquid nitrogen until measured. 57Fe
Mo¨ssbauer spectra were obtained at 90 and at 4.1 K. The
14.4 keV gamma rays were detected using a proportional
counter. A conventional constant acceleration Mo¨ssbauer
spectrometer with a 3.7 GBq (100 mCi) 57Co source in a Rh
matrix, held at room temperature, was used. Each sample
was measured for at least 48 h and at least 40 106 counts
per channel (256 channels) were obtained. The velocity
scales were calibrated with a a-Fe foil absorber at room
temperature and isomer shifts are quoted with respect to the
centroid of these spectra. The source was scanned over two
velocity ranges:  4 to + 4 and  11 to + 11 mm/s. A
temperature-controlled steady flow nitrogen cryostat was
used for measurements at 90 K. A liquid helium bath
cryostat served for measurements at 4.1 K. In order to
minimize the background due to possible iron content of
the cryostats windows, both cryostats were equipped with
Al-coated Mylar windows. The background could be due to
iron in the windows of the detector, iron in the windows of
the cryostats or traces of iron in sample holders. To check
for the presence of these artifacts, measurements of the
background in the liquid nitrogen and in the liquid helium
cryostats were performed. A sample holder filled with
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measured with statistics of over 90 million counts per
channel (256 channels). These background spectra were
then subtracted from the spectra obtained with the brain
samples. Spectra were analyzed by least squares computer
fits, assuming Lorentzian line shapes.
2.2. ELISA studies
The ELISA method was applied to determine the con-
centration of H and L ferritins and the H/L ratio in control
and parkinsonian SN, using monoclonal antibodies specific
to H(rHO2) and L(LFO3) subunits of ferritin [24,25] and
human H- and L-recombinant ferritins as standards. The
studies were performed on 11 control and 6 PD samples.
(Preliminary data, based on fewer samples, were published
in a conference abstract [26]). The age at death was 72F 5
years in control subjects and 73F 5 years in PD. The
duration of PD ranged between 6 and 8 years and the
patients were in advanced stages of the disease (4 and 5
according to Hoehn and Yahr scale [23]). All control
subjects died of non-neurological causes.
Frozen brain tissues, separated at autopsy as described
above, were homogenized in 20 mM TRIS with 1 mM
sodium azide and 1 mM phenylmethylsulfonyl fluoride
(Sigma) at pH 7.4 (10 ml buffer per 1 g of tissue). The
solutions were then centrifuged for 10 min at low speed of
2000 g and the supernatant was collected for analysis.
Multiwell plates (Sigma) were coated with 100 Al per well
of a solution of 10 Ag/ml of antibodies in 50 mM carbonate
buffer at pH 9.6 and incubated for 2 h at 37 jC. The plates
were then rinsed three times in phosphate buffered saline
containing 0.05% Tween 20. In order to block nonspecific
binding to the plates, they were incubated for 1 h at 37 jC
with 2% bovine serum albumin in phosphate buffered
saline. For calibration, a standard curve was obtained from
solutions of recombinant H and L human ferritins in
phosphate buffered saline with 0.05% Tween 20 containing
1% bovine serum albumin. The plates were covered with
known concentrations, ranging between 4 and 500 ng/ml of
recombinant H or recombinant L human ferritins [25,27].
For H analysis the supernatant obtained from the homoge-
nized tissues was diluted 1:120, 1:240, 1:480, 1:960 in
phosphate buffered saline with 0.05% Tween 20 and 1%
bovine serum albumin for each sample. For L analyses the
dilutions were 1:30, 1:60, 1:120, 1:240. The different
dilutions used for H and L subunits determination were
dictated by the different concentrations of the subunits in the
tissues. One hundred microliters of standards or sample was
added to the wells and incubated at 37 jC for 1 h. Plates
were then rinsed three times with phosphate buffered saline
and 0.05% Tween 20 and drained. The plates were then
incubated with 100 Al per well of horseradish peroxidase-
labeled antibodies in phosphate buffered saline with 0.05%
Tween 20 and 1% bovine serum albumin for 1 h at 37 jC.
Plates were rinsed again three times in phosphate bufferedsaline with 0.05% Tween 20 and drained. The horseradish
peroxidase activity (corresponding to H and L subunits
concentrations) was detected by o-phenylenediamine
dichloride in the presence of 0.02% H2O2. The color was
allowed to develop for 15 min and the reaction was stopped
by addition of 50 Al of 2 M H2SO4. The absorption of each
well was measured at 490 nm using a Bio-Rad plate reader.
2.3. Statistical analysis
The uncertainties of the Mo¨ssbauer parameters are given
at the level of one standard deviation. The Cochran–Cox
test [28] was used to evaluate the statistical significance of
the differences obtained by Mo¨ssbauer measurements be-
tween control and parkinsonian SN. This test was also used
to evaluate the statistical significance of the differences of
the levels of H and L subunits and the H/L ratio between
control and parkinsonian SN samples obtained from ELISA
studies. The Cochran–Cox test deals with the comparison
between means obtained from two sets of measurements,
with different and small numbers of samples [29,30].3. Results
3.1. Mo¨ssbauer studies
The spectra obtained with distilled water absorbers in the
nitrogen and helium cryostats (background spectra) are
shown in Figs. 1(a) and 2(a). In the background spectrum
at 90 K, no significant signal was observed. In the back-
ground obtained with the He cryostat (at 4.1 K) this signal
was less than 0.015%.
Typical Mo¨ssbauer spectra obtained from parkinsonian
and control SN at 90 K (stripped of the background) are
shown in Fig. 1(b) and (c). Fig. 2(b) shows a background
stripped spectrum obtained at 4.1 K from the PD sample.
The spectra at 90 K are composed of a slightly asymmetric
doublet and the 4.1 K spectrum consists, within the limits of
error, of a pure sextet.
As a first approximation, the 90 K spectra were analyzed
with one doublet composed of two equal lines. The Mo¨ss-
bauer parameters of the doublet, obtained in this way from
all measured SN samples at 90 K, were: IS (isomer
sh i f t ) = 0 .47 F 0 .01 mm/s and QS (quadrupo le
splitting) = 0.69F 0.01 mm/s. The sextet observed at 4.1
K gave a hyperfine field of He ff = 49.2 F 0.5 T,
IS = 0.49F 0.02 mm/s and QS= 0.0. These parameters are
very similar to those obtained from various ferritins [31] and
from NM isolated from SN [12]. The main difference
between Mo¨ssbauer spectra of ferritin iron and iron in
NM isolated from SN was detected in the 90 K spectra,
where ferritin spectra display a pure doublet, whereas NM
spectra show a superposition of a doublet and a sextet. This
indicates different blocking temperatures in the two com-
pounds, which are well above 90 K for NM and about 40 K
Fig. 3. Distributions of the asymmetry coefficients for control (top) and
parkinsonian (bottom) SN samples.
Fig. 1. (a) Mo¨ssbauer background spectrum obtained with a 57Co source
and a distilled water absorber at 90 K in the nitrogen cryostat; (b) a typical
spectrum obtained from parkinsonian SN at 90 K (stripped of the
background) showing an asymmetry coefficient of 1.12; (c) a spectrum
(stripped of the background) obtained from control SN at 90 K showing an
asymmetry coefficient of 1.06. The solid lines show the computer fits to the
experimental spectra with two lines of equal areas and different line widths.
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of SN at 90 K, no sextet was observed; however, due to the
small effect and relatively large spread of statistical errors of
the background points, a sextet could be hidden in this
background. We tried to estimate the amount of NM iron
that could be present in the sample and not be detected byFig. 2. (a) Mo¨ssbauer background spectra obtained with a 57Co source and a
distilled water absorber at 4.1 K in the helium cryostat and (b) a spectrum
obtained from the same parkinsonian SN as in Fig. 1(b) at 4.1 K (stripped of
the background). The solid line shows the computer fit to the experimental
spectrum.us. To accomplish this, we included a simulated NM iron
spectrum with parameters obtained from the spectra of NM
isolated from control SN (Ref. [12] and our own unpub-
lished data) in the theoretical spectra that were computer-
fitted to the experimentally observed spectra in whole
tissues of SN. The quality of the computer fits, as measured
by the chi-square of the fit between the simulated and
experimental spectra, did not change significantly if a NM
iron subspectrum, whose intensity was up to 15% of the
overall spectral area, was included in the fitted spectra. We
can conclude therefore that if less than 15% of the iron in
SN is bound to NM, it could not be detected in our
measurements.
In order to quantify the slight asymmetry detected in the
90 K spectra from whole SN tissues, the spectra were fittedTable 1
Concentrations of H and L chains of ferritin in control SNs
Sample no. Concentration
of H ferritin
(ng/mg wet tissue)
Concentration
of L ferritin
(ng/mg wet tissue)
H/L ratio
1 310 49 6.3
2 918 242 3.8
3 717 194 3.7
4 435 65 6.7
5 403 181 2.2
6 800 119 6.7
7 348 49 7.0
8 203 30 6.7
9 318 72 4.4
10 245 62 3.9
11 368 91 4.0
MeanF S.E. 460F 70 105F 21 5.5F 0.5
Table 2
Concentrations of H and L chains of ferritin in parkinsonian SNs
Sample no. Concentration
of H ferritin
(ng/mg wet tissue)
Concentration
of L ferritin
(ng/mg wet tissue)
H/L ratio
1 912 64 14.4
2 602 30 20.0
3 419 31 13.7
4 344 47 7.3
5 400 80 5.0
6 165 33 5.0
MeanF S.E. 474F 105 47F 8 10.9F 2.5
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widths of the lower velocity line to that of the higher
velocity line was defined as the asymmetry coefficient.
The distributions of the obtained values of the asymmetry
coefficients for control and PD-SN samples are shown in
Fig. 3. These histograms show clearly a difference in the
distributions of the asymmetry coefficients obtained from
PD and control samples. The weighted mean of the
asymmetry coefficient and its standard deviation were
calculated for parkinsonian and control samples. This
weighted mean for the asymmetry coefficient for parkin-
sonian SN is 1.14F 0.03 and 1.06F 0.02 for controls. The
difference between these values is statistically significant
with P < 0.05.
The stripped 4.1 K spectra show, within the limits of
error, a pure sextet with broadened lines. The line broaden-
ing is probably caused by a distribution of hyperfine fields,
which is expected due to the non-homogeneous character of
the iron clusters. No appreciable difference is observed in
the 4.1 K spectra between control and PD.
3.2. ELISA studies
The concentrations of H subunits found in our measure-
ments by ELISA do not differ significantly between par-
kinsonian and control SN, ranging between 203 and 918 ng/
mg wet tissue in control (mean: 460F 60) and between 165
and 912 ng/mg wet tissue in PD (mean: 470F 100). The
difference in the levels of L subunits between parkinsonian
and control SN is significant with P < 0.05. These levels are
between 30 and 242 ng/mg wet tissue in control SN (mean:
105F 20) and between 30 and 80 ng/mg wet tissue in
parkinsonian SN (mean: 47F 8). The data are presented
in Tables 1 and 2. The difference in the H/L ratio between
PD (10.5F 2.5) and control (5.1F 0.5) is on the border of
statistical significance (P= 0.05).4. Discussion
When iron occupies one single site in a homogeneous
polycrystalline paramagnetic compound, the Mo¨ssbauer
spectrum shows a well-defined symmetric doublet, com-
posed of two narrow lines. An asymmetric doublet indicatesthat either the iron compound is not homogeneous, or that
more than one iron compound, yielding slightly different
Mo¨ssbauer parameters (isomer shifts and quadrupole split-
tings), are present in the sample. The Mo¨ssbauer effect alone
can sometimes not distinguish between these two possibil-
ities. In an inhomogeneous compound, iron may occupy
slightly different environments, yielding a series of slightly
different Mo¨ssbauer parameters. An asymmetric spectrum
could be a superposition of many spectra, each one with
slightly different parameters, as in an inhomogeneous com-
pound, or could be a superposition of two spectra only, if
two different iron compounds, yielding only slightly differ-
ent parameters, are present in the sample. It may of course
also be a combination of both. As mentioned above, ferritin
iron is not a fully homogeneous stoichiometric compound,
but a mixture of a not well-defined iron-oxyhydroxide with
varying amounts of phosphoric-oxides [32]. This mixture is
different in ferritins from different sources and may cause
different Mo¨ssbauer parameters. The observed difference in
the asymmetry coefficient may thus be due to minor changes
in the iron core composition and structure of ferritin in PD
and control or it may be that the slightly higher asymmetry
of the doublets obtained at 90 K in PD, compared to control
SN samples, could be caused by an additional different
trivalent iron-compound present in parkinsonian SN.
The ferritin-like iron in NM might also be somewhat
different in control and PD, but in advanced stages of PD
only very little NM is present in SN [33] and it is therefore
unlikely that a change in the structure of the iron compound
in NM could be the cause for the observed asymmetry.
An additional iron compound in parkinsonian SN, caus-
ing the greater asymmetry, may be formed after the release
of iron from ferritin. This, possibly low molecular weight,
iron compound, may yield a magnetically split or relaxation
spectrum at 4.1 K and therefore would not be distinguished
from the ferritin-like Mo¨ssbauer spectra at this temperature.
If such iron is present in parkinsonian SN, it may lead to the
overproduction of free radicals, triggering oxidative stress
and cell death in parkinsonian SN.
Iron released from deteriorating NM might also be the
source of such iron in parkinsonian SN [6]. A recent electron
paramagnetic resonance study, which compared NM isolated
from five SN from control brains with NM isolated from five
SN from parkinsonian brains, demonstrated the disappear-
ance of EPR signals in the g = 2.0–2.4 region in parkinso-
nian samples [34]. This may suggest a local breakout of
some ferrihydrite clusters, leading to the formation of EPR-
silent Fe(III) centers, which might be equated with the iron
represented by the additional iron compound causing the
asymmetry in the Mo¨ssbauer doublet. This assumption is
supported also by recent magnetic susceptibility measure-
ments on NM isolated from control and parkinsonian SN
[35]. These measurements showed lower magnetization in
PD samples, which was attributed to a lower iron concen-
tration in parkinsonian NM. As suggested by the authors,
iron could have migrated from NM to the cytosol. This
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partly be present in the cytosol as a low molecular weight
compound. The higher asymmetry obtained from Mo¨ssbauer
measurements on whole PD-SN may be due to such trivalent
iron, which may possibly be the source of iron leading to the
Fenton reaction. As the difference between the average
asymmetry coefficients is about 8%, this may be the
percentage of iron present in such a compound.
In another recent study, Faucheux et al. [36 ] found a
huge increase (about 10 times) of the iron content in pars
compacta of SN (SNpc) in PD compared to control SNpc,
using Perls’ prussian blue reaction as described by Smith et
al. [37]. This method is sensitive only to redox active iron
and only some of the tissue-bound iron is available for redox
activity [37]. Ferritin or NM-bound iron seems not to be, as
demonstrated by the small staining obtained in control
tissues of both SN [36] and hippocampus [37]. The large
difference found by Faucheux et al. in the redox active iron
content between PD and control SNpc may be due to iron,
which is safely stored in NM or ferritin in control, but is
present as redox active iron in the pathological tissue. This
may be the same iron causing the increased asymmetry in
the Mo¨ssbauer spectra and the change in the EPR spectra.
Faucheux et al. [36] found no up-regulation of ferritin
subunits in PD-SNpc compared to control, which indicates
that the redox active iron is not taken up by ferritin in this
part of SN. Few cells near melanized neurons showed an
increase in ferritin mRNA, which indicates the presence of
more ferritin in a subset of glial cells near neurons, pointing
to a different intracellular location of iron in PD compared
to control.
Faucheux et al. [36] did not find any difference in the
levels of H- and L-ferritins, between parkinsonian and
control SN pars compacta, whereas our data, as well as
those obtained by Connor et al. [7] on whole SN, showed a
considerable decrease of L-ferritin in PD. Pars compacta
contains mainly neurons, while pars reticulata has more glial
cells. Ferritin in neurons is H-rich, while glial ferritin is L-
rich [11]. The whole SN samples contained certainly more
glial cells and therefore the change in L-ferritin levels found
in our study might represent changes in these cells.
The substantial decrease of L subunits in parkinsonian
SN compared to elderly control reported here is similar to
that obtained by Connor et al. [7]; however, the concen-
trations measured for L-ferritin, and to a lesser extent for H-
ferritin, are different. The concentrations in elderly control
obtained by us are similar to those found by Zecca et al. [6].
The different results obtained might be due to the different
methods used. Here, as in Zecca et al. [6], the ELISA
sandwich method with monoclonal antibodies was used,
which might underestimate the ferritin levels [24] compared
to a quantitative dot/blot assay used by Connor et al. [7].
The difference might also be due to different amounts of
humidity in the samples or to different standards used.
According to the results obtained here, as well as to those
obtained by Connor et al. [7], it seems that in wholeparkinsonian SN, L subunits are either less synthesized or
more vulnerable to destruction than H subunits. The lower
levels of L chains in parkinsonian SN may point to a
decreased potential to store iron in a safe form within the
ferritin shell. With the lack of L-chains, iron core formation
is slowed down and the H-chains may not be able to empty
their ferroxidase centers in order to take up more iron and
thus might not be able to detoxify the tissues from accu-
mulating free iron.
It is, however, hard to know what precedes what—the
destruction (or lower synthesis) of L subunits or NM or the
presence of free iron. It might be a process which feeds
itself. As iron in SNpc is mainly stored in NM, the
deterioration of NM in PD must leave free iron, unattached
to NM. As no up-regulation of ferritin was found in SNpc
[36], this iron is not taken up by ferritin, but is probably
expelled to nearby glial cells. The decrease in L-subunits in
whole SN thus prevents the uptake of this iron by ferritin,
leaving it possibly in a toxic form, which may cause further
deterioration of nervous cells. The 8% change in the
asymmetry observed in the Mo¨ssbauer spectra of PD-SN
is probably due to this toxic iron, leading to oxidative stress.
Whether there is more iron in parkinsonian SN compared
to control [21,22] or the same concentration [14,38], the
lower concentration of ferritin in PD might not be enough to
detoxify the parkinsonian tissues and may cause free poi-
sonous iron to be present in parkinsonian SN. It should be
kept in mind, though, that oxidative stress may be only one
of many ways leading to the death of nervous cells in the
disease and a combination of several factors might be
involved in this process.Acknowledgements
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